[1] [1] D.-E. Drayer, “Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overview," Clin. Pharmacol. Ther. 40, 125-133 (1986).

[2] [2] B. Waldeck, “Biological significance of the enantiomeric purity of drugs," Chirality 5, 350-355 (1993).

[3] [3] W.-H. De Camp, “Chiral drugs: The FDA perspective on manufacturing and control," J. Pharmaceut. Biomed. Anal. 11, 1167-1172 (1993).

[4] [4] L. Rigoni, S. Venti, M. Bevilacqua, R. Bucci, A.-D. Magrì, A.-L. Magrì, F. Marini, “Quantification of the enantiomeric excess of two APIs by means of near infrared spectroscopy and chemometrics," Chemometr. Intell. Lab. 133, 149-156 (2014).

[5] [5] P. Lu, L. You, H.-Y. Hua, “Clinical observation on the e±cacies of praziquantel for liver fibrosis in patients with advanced schistosomiasis," J. Trop. Dis. Parasitol. 4, 204-207 (2015).

[6] [6] Y. Yan, J.-M.Wang, Y. Jiang, X.-H. Li, Y. Liu, C.-G. Zhu, Y.-J. Shi, “Experiment of praziquantel rectal administration in treatment of schistosomiasis in mice," Chin. J. Schisto Control 6, 674-676 (2011).

[7] [7] W.-L. Wu, X.-Z. Zhou, Y.-Y. Huang, “Longterm e±cacy of pyquiton on Schistosomiasis japonica," Chin. J. Infect. Dis. 4, 21-24 (2004).

[8] [8] Z.-J. Wen, “Therapeutic effect observation of schistosomiasis chronic diarrhea patients are treated by spraying praziquantel solution under the colonoscope and oral praziquantel tablet," J. Pathog. Biol. 11, 1031-1032 (2013).

[9] [9] WHO, “Prevention and control of schistosomiasis and soil-transmitted helminthiasis," World Health Organization Technical Report 912, i (2002).

[10] [10] M. Tanaka, H. Ohmae, H. Utsunomiya, T. Nara, Y. Irie, K. Yasuraoka, “A comparison of the antischistosomal effect of levo- and dextro-praziquantel on Schistosoma japonicum and S. mansoni in mice," Am. J. Trop. Med. Hyg. 41, 198-203 (1989).

[11] [11] Y.-H. Liu, M.-X. Qian, X.-G. Wang, J. Jia, Q.-N. Wang, Y.-F. Jiang, R.-Q. Wang, S.-H. Yan, B.-Y. Chen, J.-S. Li, “Comparative e±cacy of praziquantel and its optic isomers in experimental therapy of Schistosomiasis japonica in rabbits," Chin. Med. J. 99, 935 (1986).

[12] [12] S.-H. Xiao, B.-A. Catto, “Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni," J. Infect. Dis. 159, 589-592 (1989).

[13] [13] Y. Zheng, L. Dong, C. Hu, B. Zhao, C. Yang, C. Xia and D. Sun, “Development of chiral praziquantel analogues as potential drug candidates with activity to juvenile Schistosoma japonicum," Bioorg. Med. Chem. Lett. 24, 4223 (2014).

[14] [14] S.-H. Xiao, J.-Q. You, J.-Y. Mei, Y.-Q. Hu, D.-H. Zhou, B.-A. Catto, “In vitro and in vivo effect of levopraziquantel, dextropraziquantel versus racemic praziquantel on different developmental stages of Schistosoma japonicum," Chin. J. Parasitol. Parasit. Dis. 16, 335 (1998).

[15] [15] D. Cioli, S.-S. Botros, K. Wheatcroft-Francklow, A. Mbaye, V. Southgate, L.-A. Tchuente, L. Pica-Mattoccia, A.-R. Troiani, S.-H. El-Din, A.-N. Sabra, J. Albin, D. Engels, M.-J. Doenhoff, “Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates," Int. J. Parasitol. 34, 979-987 (2004).

[16] [16] P. Olliaro, P. Delgado-Romero and J. Keiser, “The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer)," J. Antimicrob. Chemoth. 69, 863-870 (2014).

[17] [17] H.-N.Wang, Z.-Z. Fang, Y. Zheng, K. Zhou, C.-Y. Hu, K.-W. Krausz, D.-Q. Sun, J.-R. Idle, F.-J. Gonzalez, “Metabolic profiling of praziquantel enantiomers," Biochem. Pharmacol. 90, 166-178 (2014).

[18] [18] M. Yang, W.-Y. Zhong, W. Hou, “Advances in research on analytical methods of chiral drugs," Prog. Pharm. Sci. 38, 209-214 (2014).

[19] [19] L.-X. Lin, X.-H. Xue, M.-F. Fan, “Analysis of pyquiton by reversed phase high-performance liquid chromatography," Acta Pharmaceut. Sin. 3, 224-228 (1985).

[20] [20] X.-H. Zheng, Q. Shao, H.-Y. Jing, “Enantiomers detection of praziquantel intermediates by RPHPLC after GITC pre-column derivatization," WORLD SCI-TECH R&D 3, 626-629 (2016).

[21] [21] Q.-Z. Wu, R. Chen, S.-L. Qiao, “Enantiospecific analysis of pregabalin by HPLC with chiral precolumn derivatization," J. China Pharm. Univ. 6, 523-526 (2007).

[22] [22] Q.-Q. Li, L.-J. Wu, W. Liu, J.-L. Cao, X. Duan, Y. Huang, S.-G. Min, “UV spectroscopy coupled with partial least squares to determine the enantiomeric composition in chiral drugs," Spectrosc. Spect. Anal. 2, 500-504 (2011).

[23] [23] D.-C. Gu, M.-J. Zou, X.-X. Guo, P. Yu, Z.-W. Lin, T. Hu, Y.-F. Wu, Y. Liu, J.-H. Gan, S.-Q. Sun, X.-C. Wang, C.-H. Xu, “A rapid analytical and quantitative evaluation of formaldehyde in squid based on Tri-step IR and partial least squares (PLS)," Food Chem. 229, 458-463 (2017).

[24] [24] A. Palou, A. Miro, M. Blanco, R. Larraz, J.-F. Gomez, T. Martínez, J.-M. Gonzáalez and M. Alcala, “Calibration sets selection strategy for the construction of robust PLS models for prediction of biodiesel/diesel blends physico-chemical properties using NIR spectroscopy," Spectrochim. Acta A: Mol. Biomol. Spectrosc. 180, 119-126 (2017).

[25] [25] Y.-Z. Liang, R.-Q. Yu, Y.-L. Xie, “Partial leastsquares regression applied to pharmaceutical analysis," Anal. Chem. 7, 588-592 (1989).

[26] [26] L.-M. De Souza, F.-B. De Santana, L.-C. Gontijo, S.-J. Mazivila, N.-W. Borges, “Quantification of adulterations in extra virgin flaxseed oil using MIR and PLS," Food Chem. 182, 35-40 (2015).

[27] [27] J.-B. Liu, Y. Ren, P.-X. Zhang, “Spectrophotometric determination of pharmaceutical compositions by partial least squares method and principal component regression method," Anal. Chem. 10, 887-892 (1990).

[28] [28] K.-W. Busch, I.-M. Swamidoss, S.-O. Fakayode, M.-A. Busc, “Determination of the enantiomeric composition of guest molecules by chemometric analysis of the UV-visible spectra of cyclodextrin guest host complexes," J. Am. Chem. Soc. 125, 1690-1691 (2003).

[29] [29] Q.-Q. Li, Y. Huag, J. Duan, L.-J. Wu, G. Tang, Y.-W. Zhu and S.-G. Min, “Sucrose as chiral selector for determining enantiomeric composition of metalaxyl by UV vis spectroscopy and PLS regression," Spectrochim. Acta A: Mol. Biomol. Spectrosc. 101, 349-355 (2013).

[30] [30] C.-D. Tran, D. Oliveira, V.-I. Grishko, “Determination of enantiomeric compositions of amino acids by nearinfrared spectrometry through complexation with carbohydrate," Anal. Chem. 75, 6455-6462 (2003).

[31] [31] S.-O. Fakayode, I.-M. Swamidoss, M.-A. Busch, K.-W. Busch, “Determination of the enantiomeric composition of some molecules of pharmaceutical interest by chemometric analysis of the UV spectra of guest host complexes formed with modified cyclodextrins," Talanta 65, 838-845 (2005).